Ashwagandha and its active ingredient, withanolide A, increase phosphorylation of TrkB in cultured hippocampal neurons

ABSTRACT

Aims: To primary rat embryonic hippocampal neurons in culture, ashwagandha or one of its active ingredients, withanolide A were added in the presence or absence of nutrient supplementation and then assayed for activity of the BDNF receptor, TrkB.
Study design: Primary hippocampal neurons were cultured and grown in nutrient-rich or nutrient-poor medium. Ashwagandha or withanolide A were then be added to both types of media with or without an inhibitor of TrkB or either the PI-3K or MAPK pathway.
Place and Duration of Study: Department of Biological Sciences, California State University, Los Angeles, CA, USA, between July 2021 and August 2022.
Methodology: Rat embryos were removed by cesarean section from mother rats at 18 days' gestation and the hippocampi of the former dissected, plated into culture dishes, and treated with the appropriate drug(s) (see Study Design above). After 4 days, neurons were harvested for Western blotting. Optical density of Western blot bands were quantified and statistically analyzed in a 2-way ANOVA, using a level of statistical significance at $P < .05$.
Results: Under normal conditions (with N2 supplement), ashwagandha, but not withanolide A, increased phospho-TrkB immunoreactivity when compared to the effects of vehicle (controls, $F_{(11, 24)} = 22.48$, $P < .001$), although withanolide A did not quite reach statistical significance ($P = .069$) when compared to that of the controlled condition. Likewise, under nutrient-deprived conditions, both ashwagandha and withanolide A also increased phosphorylation of TrkB when compared to that of vehicle-nutrient-deprived conditions ($P < .0001$). The same results were obtained in the presence of inhibitors of TrkB itself and the PI-3K (ashwagandha, $P < .001$; withanolide A, $P < .001$) and MAPK (ashwagandha, $P = .027$; withanolide A, $P = .045$) pathways.
Conclusion: Ashwagandha or withanolide A activates TrkB, in nutrient-deprived hippocampal neurons, underscoring its role in neuronal survival signaling.

Keywords: Ashwagandha, depression, stress, hippocampal neurons, TrkB, BDNF, PI-3K, MAPK

1. INTRODUCTION

By now, it is well-known that in the central nervous system (CNS), the hippocampus is one of structures that is most affected by ~~the ravages of~~ mood disorders [1,2,3] although this effect is not universal [4], depending on the type of mood disorder [1]. Over the past several decades, a wealth of evidence has emerged, showing that such mood disorders may be ameliorated by physical exercise,

23 which is a putative releaser of circulating neurotransmitters [5,6,7,8]. Indeed, their extended
24 residence time in central synapses and the release of these neurotransmitters into the systemic
25 circulation is the basis of antidepressant medications [9] and the antidepressant effects of physical
26 exercise [10,11,12]. The binding of these neurotransmitters to their respective receptors has been
27 shown to activate pro-survival neuronal signaling of brain-derived neurotrophic factor (BDNF) [3,
28 13,14], Akt [15,16,17], MAPK [13,18,19,20], and CREB [13,20,21], which are decreased in
29 depression [20] and which are part and parcel of neurite outgrowth [8,22] and neuronal survival [22].

30 Several years ago, our laboratory provided evidence that in tissue culture, embryonic
31 hippocampal neurons can be stressed by depriving them of certain nutrients [23,24]. These nutrients
32 comprise a mixture, called N2, which consists of insulin, progesterone, putrescine, selenium dioxide
33 and human transferrin. After being allowed to acclimate for several hours following culturing, neurons
34 were deprived of N2. It was shown that the addition of various compounds known to increase cell
35 survival, such as norepinephrine [13,23], serotonin [24], or antidepressants [24], could be
36 neuroprotective by increasing BDNF expression and activating the Akt/PI-3K and MAPK cascades
37 and subsequent phosphorylation of CREB [16], as well as increased dendritic lengths and neuronal
38 survival [2,22,25]. Thus, we proposed that this model is analogous to the dendritic pruning and
39 neuronal death that hippocampal neurons undergo in the wake of mood disorders [2].

40 Ashwaghanda (*Withania somnifera*, WS, Indian ginsing) has been shown to improve cognition
41 and mood in depressed people by decreasing cortisol levels [26,27]. Because there is much evidence
42 that WS has ameliorative properties in both peripheral [28] and central [29,30] disorders (also see
43 [22] and references cited therein), we evaluated its cell survival-promoting effects in our tissue culture
44 model of nutrient deprivation stress.

45 More recently, our laboratory reported that, in hippocampal neurons in cuture, BDNF and Akt,
46 MAPK, and CREB phosphorylation, as well as neuronal survival, are decreased in response to
47 nutrient-deprived conditions, while WS and one of its most potent active ingredients, withanolide A
48 (WA), was able to increase the immunoreactivity or phosphorylation of the afore-mentioned variables
49 under both nutrient-supplemented and –deprived condtions relative to those of controls [22].

50 The current study is an addendum to Hwang et al. [22], where herein, TrkB phosphorylation
51 was evaluated in response to nutrient-supplemented or –deprived, and WS- or WA-supplemented
52 conditions under PI-3K/Akt or MAPK cascade blockade in embryonic hippocampal neurons. Others
53 have noted that, not surprisingly, that expressison of BDNF and its receptor covary [3,31] in terms of
54 activation [32]. Specifically, we hypothesize that TrkB phosphorylation will be decreased under
55 nutrient-deprived conditions, as well as under conditions of TrkB, PI-3K and MAPK inhibition, but will
56 be ameliorated in the presence of WS or WA.

57
58
59 **2. MATERIALS AND METHODS**

60 2.1. Plant material used

61 Withania somnifera (L.) Dunal is a member of the family Solanaceae, which is listed in
62 www.theplantlist.org and the World Checklist of Selected Plant Families (WCSP). For this study, we
63 used an ashwagandha tincture in methanol.

64

65 2.2. HPLC analysis of Withanolide A and Ashwagandha

Analysis of WS and WA were conducted using HPLC and were taken from the same stock, stored at -20°C, as performed previously [22].

2.3. Animal Care and Handling

All rat handling were conducted in strict accordance with the National Research Council's Guide for the Care and Use of Laboratory Animals (1996). Maximal effort was placed on minimizing the suffering of any rats used in this study. All experiments were approved by the California State University Institutional Review Board and the Animal Care Committee.

2.4. Antibodies, chemicals and assays

N2 was purchased from Invitrogen (Grand Island, NY, USA), is composed of insulin, progesterone, putrescine, selenium dioxide and human transferrin and dissolved in minimal essential medium (MEM) with Earle's salts at a final culture concentration of 1% as previously described [24]. Anti-phospho-TrkB and anti-TrkB were both purchased from Cell Signaling Technologies (Danvers, MA, USA). Anti-mouse IgG and anti-rabbit IgG were purchased from Amersham Pharmacia-Biotech (Piscataway, NJ, USA). WA was purchased from Sigma (St. Louis, MO, USA); K252a was purchased from Calbiochem (LaJolla, CA, USA); LY294002 and PD98059 were purchased from Promega (Madison, WI, USA). Finally, WS was purchased from Sprouts grocery store (Whittier, CA, USA). This tincture comes in 80 % methanol, which was evaporated off in a savant centrifuge till only a sticky brown/yellow pellet remained. This pellet was then reconstituted in DMEM to achieve the desired concentrations of 40 µg/ml [22] and has been stored at -20°C.

2.5. Hippocampal Dissection at Embryonic Day 18 (E18) and Tissue Culture

Primary hippocampal neurons were obtained from rat embryos at 18 days in gestation exactly as described previously [24]. Briefly, pregnant female rats (Sprague-Dawley, 2 months of age, 250 g, Charles River, Wilmington, MA, USA) at 18 days gestation were sacrificed with an overdose of isofluorane, followed by rapid decapitation and the embryos removed via cesarean section. Both hippocampi were dissected from each embryo into Ca-Mg-free DMEM and then rinsed twice into 15-ml conical tubes to which 0.125% trypsin was added for 5-10 min in a 37°C water bath with gentle inversion every 2-3 minutes. The reaction was then quenched in 10% fetal bovine serum (FBS)/DMEM in two volumes to stop the reaction. Hippocampi were then centrifuged at 200 g for 5 min and the resultant pellet resuspended in 2-5 ml DMEM. The hippocampi were then triturated with glass Pasteur pipettes to mechanically dissociate the neurons from each other and connective tissue. They were then filtered through a 40-µm cell strainer (Falcon) into new conical tubes and then resuspended up to 5 ml DMEM. Cells were then counted in a hemacytometer to quantify and then plated at a density of 50,000 cells/cm2 in a total volume of 1 ml.

2.6. Procedures

Three days following plating, in half of the culture wells, the media was replaced with fresh DMEM/1% N2, while the other half of the culture wells received fresh DMEM only (-N2, nutrient

deprivation). The cultures were allowed to adapt for six hr, followed by K252a (200 nM, [13], LY294002 (20 μM, [22]) or PD98059 (10 μM, [22]) and/or WS (40 μg/ml, [22]) or WA (20 μM, [33]). Twenty-four hr later, cells were lysed and harvested for subsequent SDS-PAGE and Western blotting (Fig. 1; see below).



Figure 1. Time-line of treatment of rat hippocamal neurons.

2.6.1. Harvesting Cultured E18 Hippocampal Neurons

Cultured hippocampal neurons were harvested exactly as described previously [24]. Briefly, the media was aspirated off and the cells scraped with a cell scraper, each well reconstituted in a total volume of 0.5 ml hot cell lysis buffer (10 mM tris-base, pH 7.4, 1% SDS). Each sample was then boiled for 5 min, triturated through a 26-G needle to sheer genomic DNA, centrifuged and the volume measured. An equal volume of gel loading buffer was then added to each sample [34]. Samples were then stored at -20°C till electrophoresis and Western blotting.

2.6.2. SDS-PAGE/Western Blotting

Electrophoreses and subsequent Western/immunoblotting were performed exactly as described previously [24]. Briefly, after protein concentrations were determined using the method of Lowry [35], 10% polyacrylamide gels were cast and then 30 μg protein of each sample was loaded therein. Following electrophoresis, proteins were electrotransferred at 80 V to nitrocellulose for 2 hr at room temperature. Blots were then probed with anti-phospho-TrkB according to manufacturer's specifications (Cell Signaling Technologies). Blots were then exposed to enhanced chemiluminescence (ECL, Amersham-Pharacia-Biotech, Piscataway, NJ, USA). Blots were then stripped (in 100 mM 2-mercaptoethanol, 2% SDS, 62.5 mM tris-HCl, pH 6.7, 55°C, 10 min, while agitating) and then re-probed with anti-TrkB according to manufacturer's specifications (Cell Signaling Technologies) and again exposed to ECL.

2.6.3. Statistical Analysis

141 Quantification of immunoreactive bands was performed using ImageJ (Rasband, W., NIH,
142 USA), to quantify lightly exposed Western blotting bands within the linear range of a standard curve.
143 The optical density of each phospho-TrkB band was divided by that of its respective loading control,
144 TrkB, to yield the corrected band intensity. Each sample had been loaded onto the gel in triplicate and
145 each Western blotting experiment for each sample performed 2-3 times.

146 For the Western blotting experiments, statistical analyses entailed a two-way analysis of
147 variance (ANOVA) to examine the main effects nutrient supplement (N2) (enriched vs. deprived
148 media) x compound (WS, WA, K252a, LY292002, and/or PD98059) on phospho-TrkB). Results were
149 considered statistically significant at $P < .05$. A significant F (ANOVA) was followed by a Fisher's
150 post-hoc test of least significant differences (PLSD) to evaluate statistically significant differences
151 among treatment groups.

152
153
154
155 **3. RESULTS**

156 3.1 Ashwagandha and Withanolide A Co-elute.

157 HPLC analysis showed that WS and WA were both of high purity, showing sharp and
158 consistent peaks at 227 nm as shown previously [22].

159

160 3.2 Both Ashwagandha and Withanolide A Increase TrkB Phosphorylation

161 Overall, there are statistically significant main effects for whether nutrient (N2) was present
162 ($F(1, 24) = 158.64$, $P < .001$) and the compound(s) used ($F(5, 24) = 2.82$, $P = .039$), as well as a
163 statistically significant interaction between nutrient and compound ($F(5, 24) = 14.91$, $P < .001$). Under
164 normal conditions (with N2 supplement), WS, but not WA increased phospho-TrkB immunoreactivity
165 when compared to the effects of vehicle (Veh+, Fig. 2, $F(11, 24) = 22.48$, $P < .001$), with WA not quite
166 reaching statistical significance ($P = .069$) when compared to that of the Veh+ condition. Likewise,
167 under deprived conditions (N2-), both Ws and WA also increased phosphorylation of TrkB when
168 compared to that of vehicle (Veh-, Fig. 2, $P < .0001$). Moreover, true to its function as a phospho-Trk
169 inhibitor, K252a suppressed phosphorylation of TrkB compared to those of vehicle under both
170 nutrient-supplemented ($P < .001$) and deprived ($P = .027$) conditions (Fig. 2). When combined with
171 either WS or WA, K252a significantly inhibited the phosphorylation of TrkB, compared to that of WS
172 ($P < .001$) or WA ($P < .001$) alone, respectively, under both nutrient-supplemented ($P = .006$) and
173 deprived ($P =.047$) conditions.

174

175

176

177

178



200

201 Figure 2. * Significantly different from V+; # Significantly different from V-; ** Significantly different
202 from corresponding (+) condition; @ Significantly different from corresponding condition without
203 inhibitor. All at $P < .05$.

204

205 3.3 Both Ashwagandha and Withanolide A Increase TrkB Phosphorylation Through the MAPK
206 Pathway

207 Overall, there are statistically significant main effects for whether nutrient (N2) was present
208 ($F(1, 24) = 189.04$, $P < .001$) and the compound(s) used ($F(5, 24) = 6.35$, $P < .001$), as well as a
209 statistically significant interaction between nutrient x compound ($F(5, 24) = 13.25$, $P < .001$). As in
210 Figure 1, under either nutrient-supplemented or –deprived conditions, WS, but not WA, increased
211 phospho-TrkB immunoreactivity when compared to the effects of vehicle (Veh+, Fig. 3, $F(11, 24) =$
212 26.09, $P < .001$), with WA not quite reaching statistical significance ($P = .061$) when compared to that
213 of the Veh+ condition. Likewise, under deprived conditions (N2-), both WS and WA also increased
214 phosphorylation of TrkB when compared to that of vehicle (Veh-, Fig. 3, $P < .0001$). Under normal
215 N2-suppplemented conditions, PD98059 resulted in statistically similar levels of TrkB activation,
216 whereas in N2- conditions, there was a huge significant decrease, compared to that of N2+ ($P <$
217 $.001$). When combined with either WS or WA under N2+ conditions, PD98059 failed to inhibit TrkB
218 phosphorylation, bringing its levels comparable to those of Veh+, but only slightly decreased
219 activation of the receptor in N2-deprived conditions, although these decreases were still statistically
220 lower than their respective N2+ counterparts (WSPD+, $P = .027$ and WAPD+, $P = .045$) (Fig. 3).

221



244

245

246 Figure 3. * Significantly different from V+; # Significantly different from V-; ** Significantly different
247 from corresponding (+) condition. @ Significantly different from corresponding condition without
248 inhibitor. All at $P < 0.05$.

249

250

251 3.4 Both Ashwagandha and Withanolide A Increase TrkB Phosphorylation Through the PI-3K/Akt
252 Pathway

253 Overall, there are statistically significant main effects for whether nutrient (N2) was present ($F(1, 24) =$
254 155.98, $P < .001$) and the compound(s) used ($F(5, 24) = 8.64$, $P < .001$), as well as a statistically
255 significant interaction between nutrient and compound ($F(5, 24) = 22.37$, $P < .001$) As in Figure 1,
256 under either nutrient-supplemented or –deprived conditions, WS, but not WA, increased phospho-
257 TrkB immunoreactivity when compared to the effects of vehicle (Veh+, Fig. 4, $F(11, 24) = 28.28$, $P <$
258 $.001$), with WA not quite reaching statistical significance ($P = .063$) when compared to that of the
259 Veh+ condition. Likewise, under deprived conditions (N2-), both compounds also increased
260 phosphorylation of TrkB when compared to that of vehicle (Veh-, Fig. 4, $P < .0001$), but again, WA did
261 not reach statistical significance when compared to that of the Veh+ conditions. Being a potent
262 inhibitor of the Akt pathway, LY294002 significantly inhibited phosphorylation of TrkB, compared to
263 Veh+ conditions ($P < .001$), but under nutrient-deprived conditions, LY294002 did not lower the levels
264 of TrkB activation, compared to that of Veh- conditions ($P = .078$). Even when combined with
265 LY294002 under N2+ conditions, WS and WA raised TrkB phosphorylation to levels comparable to
266 those of Veh+ and significantly higher than that of LY294002 alone ($P < .001$ for WS; $P < .001$ for
267 WA). Under N2- conditions, even when combined with LY294002, WS, but not WA, slightly, but
268 significantly ($P = .037$) raised TrkB activity, relative to that of LY294002-alone conditions (Fig. 4).

269



282

283 Figure 4. * Significantly different from V+; # Significantly different from V-; ** Significantly different
284 from corresponding (+) condition. @ Significantly different from corresponding condition without
285 inhibitor. All at $P < 0.05$.

286

287 3.5 Both Ashwagandha and Withanolide A Increase TrkB Phosphorylation - A Comparison Among
288 the three Inhibitors

289 Recall from the Results that the P level is higher for the main effects of compound ($P = .039$).
290 In the presence of N2, WS is able to increase the phosphorylation of TrkB in the presence of
291 PD98059 more than in the presence of either K252a or LY294002; without N2, WS is able to increase
292 the phosphorylation of TrkB in the presence of PD90059 more than in the presence of either K252a
293 or LY294002 ($P = .035$, Fig. 5). In the presence of N2, WA is able to increase the phosphorylation of
294 TrkB in the presence of PD98059 more than in the presence of either K252a or LY294002; without
295 N2, WA is able to increase the phosphorylation of TrkB in the presence of K252a more than in the
296 presence of either PD98059 or LY294002 ($P = .029$, Fig. 5).

297



309

310

311 Figure 5. * Significantly different from V+; # Significantly different from V-; ** Significantly different
312 from corresponding (+) condition. +, Significantly greater than WSK+ or WSLY+; ++, Significantly
313 greater than WSK- or WSLY-; +++, Significantly greater than WAK+ or WALY+; ++++, Significantly
314 greater than WAPD- or WALY-. All at $p < 0.05$.

315

316 **4. DISCUSSION**

317

318 Consistent with earlier studies showing that WS increased BDNF levels [22,36], the current
319 study found that both WS and WA increase the levels of its activated receptor as well both with and
320 without nutrient supplementation. Reliably, inhibition of TrkB was exacerbated with its inhibitor,
321 K252a, under nutrient-deprived conditions. Likewise, the same pattern of inhibition was statistically
322 significant when WS or WA were combined with either PD98059 or LY294002.

323 Thus, activation of the PI-3K/Akt cascade is bourne out by our observations that when WS or
324 WA were combined with LY294002, TrkB phosphorylation was increased to levels comparable to
325 those of controls, but not quite as high as that of WS or WA alone (Fig. 2). Even in the presence of
326 the two suppressing conditions of PD90959 and N2 deprivation, both WS or WA managed to increase
327 the levels of activated receptor to slightly lower than that of controls (vehicle +N2), but certainly much
328 higher than that of controls, WS, or WA without N2 (Fig. 3). On the other hand, when the two
329 inhibiting conditions of LY294002 and N2 deprivation were present, both WS and WA increased the
330 levels of activated receptor to lower than that of controls (vehicle +N2), but higher than that of controls
331 and WS without N2 (Fig. 4). WA, however, did not increase the doubly inhibiting conditions of –N2
332 and LY294002 (Fig. 4). When the combination treatments of Figs. 2, 3, and 4 were re-configured and
333 re-analyzed to statistically compare the triple treatments with each other (WS or WA plus inhibitor
334 plus +/- N2), WS increased TrkB phosphorylation in the presence of PD98059 more than in the
335 presence of the other two, indicating that the MAPK pathway plays a smaller role in maintenance of

336 cell survival (Fig. 5); but in the absence of N2, this effect was exacerbated, indicating that the MAPK
337 pathway plays an even smaller role in cell survival. That is, WS is able to more easily overcome the
338 inhibitory effects of PD98059 and promote cell survival to a greater extent (Fig. 5). Conversely,
339 inhibition of the receptor or of the PI-3K pathway was able to prevail over the pro-survival effects of
340 WS (Fig. 5). In the presence of N2, WA increased TrkB phosphorylation in the presence of PD98059
341 more than in the presence of either of the other two, indicating that the MAPK pathway plays a
342 smaller role in maintenance of cell survival (Fig. 5); but in the absence of N2, WA is able to more
343 easily overcome the inhibitory effects of K252a and promote cell survival to a greater extent than with
344 either PD98059 or LY294002 (Fig. 5), indicating that it is perhaps the de novo synthesis of BDNF that
345 has a more pronounced effect on cell survival. Recall that although the MAPK and Akt/PI-3K
346 cascades are activated by TrkB phosphorylation, the respective inhibitors used in this study
347 underscore their influence on CREB phosphorylation and BDNF synthesis [13,22]. Thus, with less
348 BDNF synthesized, there is less binding to TrkB and therefore, less phosphorylation. The greater
349 influence of the Akt/PI-3K cascade on TrkB phosphorylation is consistent with earlier findings that
350 both WS and WA increased the phosphorylation of Akt, but not of MAPK, under either nutrient-
351 supplemented or nutrient-deprived conditions [22].

352 Our results show that (1) all three inhibitors (one TrkB inhibitor and two cell survival signaling
353 pathway inhibitors) are able to suppress TrkB phosphorylation and that this suppression is
354 exacerbated by nutrient deprivation conditions. (2) Our tissue culture model is again validated as a
355 viable screening procedure to evaluate how much WS or WA can maintain TrkB phosporylation even
356 in light of nutrient deprivation and/or TrkB or survival pathway inhibition. And (3) our prior HPLC
357 analyses that indicated that WA was present in the WS tincture [22], supporting out observations that
358 both the WS tincture and WA exerted the same effects on intracellular signaling. In our previous
359 study [22], we found the same results with regard to BDNF, Akt and CREB activation, in response to
360 WS and WA, not to withaferin A, which is the reason for not including the latter in the current study.

361 Although the current study was conducted in tissue culture in rat embryonic hippocampal
362 neurons, the results reported herein nevertheless provide a plausible molecular mechanism
363 underlying recent clinical findings that WS improves psychological and cognitive effects in depressed
364 patients [26,38] possibly through the hypothalamus-adrenal-pituitary axis [29]. Moreover, Manchanda
365 and Kaur [39] have reported that hippocampal BDNF mRNA and phospho-Akt was increased in rats
366 fed WS leaf extracts, relative to those fed a low-fat diet, albeit not statistically so. Hippocampal TrkB
367 mRNA, however, was significantly higher in such rats compared to their low-fat diet counterparts [39];
368 this does not necessarily mean that pro-survival pathways prevail in rats fed WS leaf extracts, as (1)
369 transcription levels are not always correlated with translation levels [40,41] and (2) TrkB expression is
370 not activation, as the receptor must be phosphorylated to be activated [42,43].

371 In light of the previous [22] and the current findings, the next obvious question to ask is how
372 does WS (and WA) promote neuronal survival. Although our data show that BDNF, phospho-TrkB
373 and phospho-Akt/PI-3K pathway are up-regulated, what does WS do to initiate these pathways? We
374 had shown earlier, for example, that application of norepinephrine to hippocampal neurons resulted in
375 increased BDNF expression and increased activation of the phospho-Akt/PI-3K and MAPK pathways
376 and CREB phosphorylation [13]. Norepinephrine binds to its G-protein-coupled receptor, following
377 the protein kinase A pathway [44], leading to the phosphorylation of CREB, which takes part in the
378 transcription of BDNF and its binding to TrkB, which is then autophosphorylated, and finally,
379 activating the pro-survival Akt-PI-3K and MAPK cascades [45]. But, what about WS (and WA)?
380 What do they bind to promote cell survival through these same cascades? It is possible that they,
381 such as WA, promote cell survival [46,47] not via a receptor-mediated pathway, but through other
382 means, such as anti-oxidation [48,49].

It is well known that antidepressants or anti-anxiety medications bind to noradrenergic, serotonergic or GABAergic receptors, acting like agonists at these receptors or reuptake inhibitors (see [13], and references cited therein; [9,50]). Alternatively, Casarotto et al. [51] recently provided evidence that antidepressants bind directly to TrkB, thereby initiating a conformational change that facilitates BDNF binding and subsequent cell survival signaling, perhaps through plastic changes [52]. Using both tissue culture incubation with antidepressants, such as fluoxetine, and molecular modeling calculations and simulations, Casarotto et al. [51] provided compelling evidence that the BDNF receptor itself could be a binding site for antidepressants. It is possible, therefore, that TrkB could also offer an amenable binding site for one or more of the active ingredients of WS; WA perhaps could promote neurite outgrowth [53] via direct interaction with TrkB. Future studies must be undertaken to determine if this is feasible.

5. CONCLUSION

In the current study, we have extended previous findings that ashwagandha and one of its active ingredients, withanolide A, indeed activates the BDNF receptor, TrkB, in nutrient-deprived hippocampal neurons, underscoring its role in neuronal survival signaling.

ACKNOWLEDGEMENTS

No granting agency was involved in the planning or execution of this study.

FUNDING

College of Natural and Social Sciences, California State University, Los Angeles

COMPETING INTERESTS

Authors have declared that no competing interests exist.

AUTHORS' CONTRIBUTIONS

MC performed the experiments and statistical analyses. ARN approved the study and managed the writing. All authors read and approved the final manuscript.

ETHICAL APPROVAL

All rat handling were conducted in strict accordance with the National Research Council's Guide for the Care and Use of Laboratory Animals (1996). All experiments were approved by the California State University Institutional Review Board and the Animal Care Committee.

All authors hereby declare that "Principles of laboratory animal care" (NIH publication No. 85-23, revised 1985) were followed, as well as specific national laws where applicable. All experiments have been examined and approved by the appropriate ethics committee.

REFERENCES

1. Cao B, Passos IC, Mwangi B, Amarai-Silva H, Tannous J, Wu M-J, et al. Hippocampal subfield volumes in mood diorders. Mol Psychiatry. 2017;22:1352-1358.

2. Duman RS, Henniger GR, Nestler EJ. A molecular and cellular theory of depression. Arch. Gen. Psychiatry. 1997;54(4):597-606.

3. Phillips C. Brain-derived neurotrophic factor, depression, and physical activity: Making the neuroplastic connection. (2017). Neural Plasticity 2017;https://doi.org/10.1155/2017/7260130.

4. Hastings RS, Parsey RV, Oquendo MA, Arango V, Mann JJ. Volumetric analysis of the prefrontal cortex, amygdala, and hippocampus in major depression. Neuropharmacology, 2004;29: 952-959.

5. Ma Q. Beneficial effects of moderate voluntary physical exercise and its biological mechanisms on brain health. Neurosci Bull. 2008;24(4): 265-270.

6. Wang J, Chan X, Zhang N, Ma Q. Effects of exercise on stress-induced changes of norepinephrine and serotonin in rat hippocampus. The Chinese J. Physiol. 2013;56(5): 245-252.

454 7. Sun L, Sun Q, Qi J. Adult hippocampal neurogenesis: an important target associated with
455 antidepressant effects of exercise. Rev Neurosci 2017;28(7):693-703.

456

457 8. Cooper C, Moon HY, van Praag H. On the run for hippocampal plasticity. Cold Spring Harbor
458 Perspectives in Medicine. 2018;8(4).

459

460 9. Russo-Neustadt AA, Chen MJ. Brain-derived neurotrophic factor and antidepressant activity.
461 Current Pharmaceutical Design. 2005;11:1495-1510.

462

463 10. Meeusen R, De Mierlier K. Exercise and brain neurotransmission. Sports Med. 1995;20(3):160-
464 188.

465

466 11. Szuhany K, Otto MW. Assessing BDNF as a mediator of the effects of exercise on depression. J.
467 Psychiatr Res. 2020;123:114-118.

468

469 12. Young SN. How to increase serotonin in the human brain without drugs. J. Psychiatry Neurosci.
470 2007;32(6):394-399.

471

472 13. Chen MJ, Nguyen TV, Pike CJ, Russo-Neustadt AA. Norepinephrine induces BDNF and activates
473 the PI-3K and MAPK cascades in embryonic hippocampal neurons. Cell Signal. 2007;19(1):114-128.

474

475 14. Rasmussen P, Brassard P, Adser H, Pedersen MV, Leick L, Hart E, et al. Evidence for a release
476 of brain-derived neurotrophic factor from the brain during exercise. Exp. Physiol. 2009;94(10):1062-
477 1069.

478

479 15. Chen MJ, Russo-Neustadt AA. Exercise activates the phosphatidylinositol 3-kinase pathway.
480 Brain Res. Mol. Brain Res. 2005;135(1-2):181-193.

481

482 16. Chen MJ, Russo-Neustadt AA. Running exercise-induced up-regulation of hippocampal brain-
483 derived neurotrophic factor is CREB-dependent. Hippocampus. 2009;19(10):962-972.

484

485 17. Koo JH, Kwon IS, Kang EB, Lee CK, Lee NH, Kwon MG, et al. Neuroprotective effects of treadmill
486 exercise on BDNF and PI3-K/Akt signaling pathway in the cortex of transgenic mice model of
487 Alzheimer's disease. J. Exerc. Nutrition Biochem. 2013; 17(4):151-160.

488

489 18. Hu S, Ying Z, Gomez-Pinilla F, Frautschy SA. Exercise can increase small heat shock proteins
490 (sHSP) and pre- and post-synaptic proteins in the hippocampus. Brain Res. 2009;1249:191-201.

491

492 19. Makena N, Bugarith K, Russel VA. Maternal separation enhances object location memory and
493 prevents exercise-induced MAPK/ERK signalling in adult Sprague-Dawley rats. Metab. Brain Dis.
494 2012;27(3):377-385.

495

496 20. Wang JQ, Mao L. The ERK pathway: molecular mechanisms and treatment of depression. Mol
497 Neurobiol. 2019;56(9):6197-6205.

498

499 21. Ortega-Martinez S. A new perspective on the role of the CREB family of transcription factors in
500 memory consolidation via adult hippocampal neurogenesis. Front Mol. Neurosci. 2015;8, 46. doi:
501 10.3389/fnmol.2015.00046.

502

503 22. Hwang D, Vasquez I, Galvez L, Do H, Lopez de Santa Ana A, Matta S, et al. Ashwagandha and
504 its active ingredient, withanolide A, increase activation of the phosphatidylinositol 3' kinase/Akt
505 casade in hippocampal neurons. Eur. J. Med. Plants. 2017;20(2):1-19.

506

507 23. Patel NJ, Chen MJ, Russo-Neustadt AA. Norepinephrine and nitric oxide promote cell survival
508 signaling in hippocampal neurons. Eur. J. Pharmacol. 2010;633(1-3):1-9.

509

510 24. Yang D, Chen M, Russo-Neustadt A. Antidepressants are neuroprotective against nutrient
511 deprivation stress in rat hippocampal neurons. Eur. J. Neurosci. 2012;36(5):2573-2587.

512

513 25. Schmidt HD, Duman RS. The role of neurotrophic factors in adult hippocampal neurogenesis,
514 antidepressant treatments and animal models of depressive-like behavior. Behav. Pharmacol.
515 2007;18(5-6):391-418.

516

517 26. Remenapp A, Coyle K, Orange T, Lynch T, Hooper S, Hooper S, et al. Efficacy of Withania
518 somnifera supplementation on adult's cognition and mood. J. Ayurveda and Integrative Med.
519 2022;13:100510-100515.

520

521 27. Speers AB, Cabey KA, Soumyanath A, Wright KM. Effects of Withania somnifera (Ashwagandha)
522 on stress and the stress-related neuropsychiatric disorders anxiety, depression, and insomnia.
523 Current Neuropharmacology. 2021;19:1468-1495.

524

525 28. Paul S, Chakraborty, S, Anand, U, Dey, S, Nandy S, Ghorai M, et al. Withania somnifera (L.)
526 Dunal (Ashwagandha): A comprehensive review on ethnopharmacology, pharmacotherapeutics,
527 biomedical and toxicological aspects. Biomedicine and Pharmacotherapy, 2021;143:112175-112215.

528

529 29. Lopresti A, Smith SJ, Malvi H, Kodgule R. An investigation into the stress-relieving and
530 pharmacological actions of an ashwagandha (Withania somnifera) extract. Medicine
531 2019;98:37(e17186).

532

533 30. Akhgarjand C, Asoudeh F, Bagheri A, Kalantar Z, Vahabi Z, Shab-bidar S, et al. Does
534 Ashwagandha supplementation have a beneficial effect on the management of anxiety and stress? A
535 systematic review and meta-analysis of randomized controlled trials. Phythotherapy Res. 2022;1-10.

536

537 31. Bjorkholm C, Monteggia LM. BDNF – A key transducer of antidepressant effects.
538 Neuropharmacology, 2016;102:72-79.

539

540 32. Guo W, Ji Y, Wang S, Sun Y, Lu B. Neuronal activity alters BDNF-TrkB signaling kinetics and
541 downstream functions. J. Cell Sci. 2014;127(Pt 10):2249-2260.

542

543 33. Patil SP, Maki S, Khedkar SA, Rigby AC, Chan C. Withanolide A and asiatic acid modulate
544 multiple targets associated with amyloid-β precursor protein processing and amyloid-β protein
545 clearance. J. Nat. Prod. 2010;73(7):1196-1202.

546

547 34. Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage
548 T4. Nature. 1977;227:680-685.

549

550 35. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the Folin phenol
551 reagent. J Biol Chem. 1951;193:265-275.

552

553 36. Bhatnagar M, Meena P, Barbar S, Joshi C. Neuroprotective response of the hippocampus region
554 of the brain to Withania somnifera and Asparagus racemosus root extract: An in vitro study. J. Med.
555 Plants Res. 2013;7(13):2259-2264.

556

557 37. Bhatnagar M, Sharma D, Salvi M. Neuroprotective effects of Withania somnifera dunal.: A
558 possible mechanism. Neurochem. Res. 2009;34(11):1975-1983.

559

560 38. Gopukumar K, Thanawala S, Somepalli V, Rao TSS, Thamatam VB, Chauhan S. Efficacy and
561 safety of ashwagandha root extract on cognitive functions in healthy, stressed adults: A randomized,
562 double-blind, placebo-controlled study. Evidence-Based Complementary and Alternative Medicine.
563 2021;1-10.

564

565 39. Manchanda S, Kaur G. Withania somnifera leaf alleviates cognitive dysfunction by enhancing
566 hippocampal plasticity in high fat diet induced obesity model. BMC Complementary and Alternative
567 Medicine. 2017;17:136.

568

569 40. Narisawa-Saito M, Nawa H. Differential regulation of hippocampal neurotrophins during aging in
570 rats. J. Neurochem. 1996;67:1124-1131.

571

572 41. Moritz CP, Muhlhaus T, Tenzer S, Schulenborg T, Friauf E. Poor transcript-protein correlation in
573 the brain: negatively correlating gene products reveal neuronal polarity as a potential cause. J.
574 Neurochem. 2019;149:582-604.

575

576 42. Huang EJ, Reichardt LF. Trk receptors: Roles in neuronal signal transduction. Annu Rev
577 Biochem. 2003;72:609-642.

578

579 43. Numakawa T, Suzuki S, Kumamaru E, Adachi N, Richards M, Kunugi H. BDNF function and
580 intracellular signaling in neurons. Histol Histopathol. 2010;25:237-258.

581

582 44. Raman IM, Tong G, Jahr CE. β-Adrenergic regulation of synaptic NMDA receptors by cAMP-
583 dependent protein kinase. Neuron. 1996;16:415-421.

584

585 45. Segal RA, Greenberg ME. Intracellular signaling pathways activated by neurotrophic factors.
586 Annu Rev Neurosci. 1996;19:463-489.

587

588 46. Kuboyama T, Tohda C, Komatsu K. Neuritic regeneration and synaptic reconstruction induced by
589 withanolide A. Brit. J. Pharmacol. 2005;144:961-971.

590

591 47. Kuboyama T, Tohda C, Zhao J, Nakamura N, Hattori M, Komatsu K. Axon- or dendrite-
592 predominant outgrowth induced by constituents from Ashwagandha. Neuroreport. 2002;13(14):1715-
593 1720.

594

595 48. Baitharu I, Jain V, Deep SN, Shroff S, Sahu JK, Naik PK, et al. (2014). Withanolide A prevents
596 neurodegeneration by modulating hippocampal glutathione biosynthesis during hypoxia. PLoS One.
597 2014;9(10):e105311.

598

599 49. Durg S, Dhadde SB, Vandal R, Shivakumar BS, Charan CS. Withania somnifera (Ashwagandha)
600 in neurobehavioural disorders induced by brain oxidative stress in rodents: a systematic review and
601 meta-analysis. J. Pharm. Pharmacol. 2015;67(7):879-899.

602

603 50. Quessevuer G, Gardier AM, Guiard BP. The monoaminergic tripartite synapse: a putative target
604 for currently available antidepressant drugs. Curr. Drug Targets. 2013;14(11): 1277-1294.

605

606 51. Casarotto PC, Girych M, Fred SM, Kovaleva V, Moliner R, Enkavi G, et al. Antidepressant drugs
607 act by directly binding to TRKB neurotrophin receptors. Cell. 2021;184:1299-1313e19.

608

609 52. Pilar-Cuellar F, Vidal R, Diaz A, Castro E, dos Anjos S, Pascual-Brazo J, et al. Neural plasticity
610 and proliferation in the generation of antidepressant effects: hippocampal implication. Neural Plast.
611 2013;537265. doi: 10.1155/2013/537265. Epub 2013 Jun 19.

612

613 53. Zhao J, Nakamura N, Hattori M, Kuboyama T, Tohda C, Komatsu K. Withanolide derivatives from
614 the roots of Withania somnifera and their neurite outgrowth activities. Chem. Pharm. Bull (Tokyo).
615 2002;50(6):760-765.

616
617
618
619 **DEFINITIONS, ACRONYMS, ABBREVIATIONS**
620
621 BDNF, brain-derived neurotrophic factor; P-CREB, phospho-cyclic adenosine monophosphate
622 response element binding; DMEM, Dubecco's Modified Eagles's Medium; HPLC, high-performance
623 liquid chromatography; LY, LY294002; MAPK, mitogen-activated protein kinase; NE, norepinephrine;

624 PD, PD98059; PI-3K, phosphatidylinositol-3'-kinase; TrkB, tyrosine receptor kinase B; veh, vehicle;
625 WS, Withania somnifera; WA, withanolide A
626
627
628